UroGen Pharma

Stricter FDA Oversight And Pricing Pressures Will Limit Reach

AnalystLowTarget

Not Invested

Consensus Narrative from 8 Analysts

Published

29 Aug 25

AnalystLowTarget's Fair Value

US$16.57

13.9% overvalued

04 Sep

US$18.88

41.4%

-2.9%

41.4%

-2.9%

Edit anytime before Aug 29 10:19 PM. Then post Updates to your followers.

Author's Valuation

US$16.6

13.9% overvalued

AnalystLowTarget Fair Value

Narrative

Updates0

AnalystLowTarget Fair Value

US$16.6

13.9% overvalued

Future estimation in

% p.a.

Decrease

Increase

Current revenue growth rate

38.92%

Biotech revenue growth rate

7.41%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

Decrease

Increase

Current discount rate

6.92%

Calculation

US$66.54m

Earnings '28

18.53x

PE Ratio '28

US$1.23b

Market Cap '28

US$1.23b

Market Cap '28

60.96m

No. shares '28

US$20.22

Share Price '28

US$20.22 Share Price '28

Discounted to 2025 @ 6.86% p.a.

US$16.57

Fair Value '25